denkapparat Operations GmbH Increases Stock Holdings in AbbVie Inc. $ABBV

denkapparat Operations GmbH raised its holdings in AbbVie Inc. (NYSE:ABBV) by 23.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 2,106 shares of the company’s stock after acquiring an additional 400 shares during the quarter. denkapparat Operations GmbH’s holdings in AbbVie were worth $391,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ABBV. Brighton Jones LLC lifted its position in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the last quarter. Rice Hall James & Associates LLC raised its position in AbbVie by 9.3% during the first quarter. Rice Hall James & Associates LLC now owns 5,144 shares of the company’s stock valued at $1,078,000 after acquiring an additional 437 shares in the last quarter. Hohimer Wealth Management LLC raised its position in AbbVie by 23.4% during the first quarter. Hohimer Wealth Management LLC now owns 1,895 shares of the company’s stock valued at $397,000 after acquiring an additional 359 shares in the last quarter. Finally, Apollon Financial LLC acquired a new position in AbbVie in the first quarter valued at approximately $277,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 2.9%

ABBV opened at $225.06 on Wednesday. The firm has a market capitalization of $397.76 billion, a price-to-earnings ratio of 107.17, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company’s 50 day simple moving average is $223.67 and its two-hundred day simple moving average is $203.22. AbbVie Inc. has a 1-year low of $163.81 and a 1-year high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 EPS. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. HSBC set a $225.00 price objective on shares of AbbVie in a report on Thursday, October 2nd. Wall Street Zen raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Evercore ISI lifted their price target on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research note on Monday, September 22nd. Finally, BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $236.57.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.